Acute Myeloid Leukemia (AML)

ASH Issues Guidelines on Newly Diagnosed AML in Older Adults

Original Publication Date
Article Source
External Web Content
In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed acute myeloid leukemia (AML) in older adults. Mikkael A. Sekeres, M.D., from the…

Robert Collins, MD

Institution
Harold C. Simmons Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
A recognized leader in the field of adoptive immunotherapy, Dr. Collins specializes in blood and marrow transplantation and hematologic malignancies such as leukemia, lymphoma, myeloma, Hodgkin’s disease, and myelodysplasia. Dr. Collins earned his medical degree from the University of Missouri-Kansas City School of Medicine. He completed an internal medicine residency at Baylor University Medical Center in Dallas, as well as a fellowship in hematology and oncology at the University of California at Los Angeles. Board-certified in internal medicine and medical oncology, Dr. Collins has 25 years

Vijaya Bhatt, MD

Institution
University of Nebraska Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Vijaya Raj Bhatt graduated from Institute of Medicine, Tribhuvan University in Nepal in 2009 with a degree of Bachelor of Medicine and Bachelor of Surgery (MBBS). He then went on to do a three-year residency in internal medicine in Staten Island University Hospital in Staten Island, New York. During his residency, he was awarded the resident of the year for three consecutive years. After completing his residency, he joined the University of Nebraska Medical Center in Nebraska and completed his fellowship in hematology-oncology. He has authored or co-authored 127 articles, 18 book chapters

Pinkal Desai, MD, MPH

Institution
New York Presbyterian Hospital/Weill Cornell Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
After obtaining her MBBS at Byramjeejeebhoy Medical College in India in 2005, Dr. Desai obtained an MPH at the University of Alabama at Birmingham School of Public Health. Following her residency at Wayne State University, Detroit Medical Center, she underwent fellowship training in Hematology-Medical Oncology at Providence Hospital Medical Center, serving as Chief Fellow from 2012-2013. Dr. Desai was recruited to serve in our Leukemia Program to develop a clinical practice devoted to leukemia, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). She will be developing

Carlos E. Vigil, MD

Institution
University of Iowa Clinic and Hospitals
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
About
Carlos E. Vigil, MD, is a hematologist who holds an appointment as Clinical Assistant Professor at the University of Iowa Hospitals and Clinics. Dr. Vigil achieved his medical degree at the Universidad Peruana Cayetano Heredia in Lima, Peru, completed his residency in Internal Medicine at Henry Ford Hospital in Detroit and completed three fellowships at H. Lee Moffitt Cancer Center (Hematology-Oncology), Leukemia (M.D. Anderson Cancer Center) and Hematopoetic Stem Cell Transplant (Vanderbilt University Medical Center). Dr. Vigil is an active researcher focusing on MDS, AML and other leukemias.

FDA Grants Aspacytarabine Fast Track Status for Older Patients With AML

Original Publication Date
Article Source
External Web Content
The FDA has granted a fast track designation for aspacytarabine as treatment for acute myeloid leukemia in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy. The FDA has granted a fast track designation for…

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

Background: The median overall survival of patients with high-risk

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

Posttransplantation, glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence.Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation.

Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

The implementation of next-generation sequencing (NGS) has influenced diagnostic, prognostic, and therapeutic decisions in myeloid malignancies. However, the clinical relevance of serial molecular annotation in patients with myelodysplastic syndrome (MDS) undergoing active treatment is unknown.

Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.